Here are the 424B prospectus supplements from HCW Biologics Inc. (HCWB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HCWB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCWB filings page.
HCW Biologics Inc. is offering 2,477,292 Units, each consisting of one share of Common Stock (or a Pre-Funded Warrant in certain cases) and one Common Stock Warrant, at $0.6055 per Unit for gross proceeds of approximately $1.5 million on a reasonable best efforts basis.
Each Common Stock Warrant is exercisable for one share at an exercise price of $0.6055 and expires five years after any required Shareholder Approval. Pre-Funded Warrants are exercisable at $0.0001 and offered to avoid beneficial ownership exceeding 4.99% (or up to 9.99% at holder election). The offering is expected to close in a single issuance and delivery is anticipated on or about February 19, 2026. The Company disclosed a Nasdaq quoted share price of $0.6011 as of February 17, 2026.